On May 21, 2021, GlaxoSmithKline and Vir Biotechnology announced that the European Medicines Agencyﾒs (EMA) Committee for Human Medicinal Products (CHMP) had issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004.